These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 29251033

  • 1. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis.
    Suzuki T, Nakamura Y, Kato H.
    Mod Rheumatol; 2018 Sep; 28(5):885-889. PubMed ID: 29251033
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
    Ishiguro S, Ito K, Nakagawa S, Hataji O, Sudo A.
    Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
    Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A.
    Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
    [Abstract] [Full Text] [Related]

  • 7. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.
    Nakamura Y, Suzuki T, Yoshida T, Yamazaki H, Kato H.
    Nutrients; 2017 Apr 26; 9(5):. PubMed ID: 28445420
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
    Suzuki T, Nakamura Y, Kato H.
    Mod Rheumatol; 2019 Jul 26; 29(4):676-681. PubMed ID: 30217118
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A, Kokkoris P, Makras P.
    Metabolism; 2015 Oct 26; 64(10):1291-7. PubMed ID: 26198440
    [Abstract] [Full Text] [Related]

  • 11. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
    Nakamura Y, Kamimura M, Ikegami S, Mukaiyama K, Uchiyama S, Taguchi A, Kato H.
    BMC Endocr Disord; 2015 Dec 15; 15():81. PubMed ID: 26666998
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
    Suzuki T, Nakamura Y, Kato H.
    Nutrients; 2018 Feb 27; 10(3):. PubMed ID: 29495518
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients.
    Suzuki T, Nakamura Y, Kamimura M, Kato H.
    Bone Rep; 2018 Jun 27; 8():110-114. PubMed ID: 29955629
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.